Dark Blue Therapeutics Appoints Edwin Moses as Chairman

Dark Blue Therapeutics, a biotech firm focused on developing precision oncology medicines, has appointed Edwin Moses as the Chairman of its Board. The company is transitioning to a clinical-stage entity and views Moses as a pivotal addition for his expertise in drug discovery and development. With over three decades of board-level experience in European life sciences, Moses is recognized for his ability to guide companies through transformative phases, including IPOs and multi-million-dollar sales. His appointment is expected to accelerate Dark Blue's lead program, an oral first-in-class MLLT 1/3 degrader, towards clinical trials in acute myeloid leukemia and potentially expand its scope to include solid tumors. CEO Alastair MacKinnon expressed confidence in Moses’s ability to contribute to Dark Blue’s strategic growth and successful clinical outcomes. Moses notes the potential of Dark Blue’s innovative drug discovery approach in translating academic research into viable cancer treatments.